Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Total Debt (2018 - 2022)

Theravance Biopharma (TBPH) has disclosed Total Debt for 5 consecutive years, with $396.1 million as the latest value for Q2 2022.

  • Quarterly Total Debt rose 3.69% to $396.1 million in Q2 2022 from the year-ago period, while the trailing twelve-month figure was $396.1 million through Jun 2022, up 3.69% year-over-year, with the annual reading at $388.3 million for FY2021, 1.0% down from the prior year.
  • Total Debt for Q2 2022 was $396.1 million at Theravance Biopharma, up from $393.2 million in the prior quarter.
  • The five-year high for Total Debt was $396.1 million in Q2 2022, with the low at $229.2 million in Q4 2019.
  • Average Total Debt over 5 years is $334.0 million, with a median of $382.0 million recorded in 2021.
  • The sharpest move saw Total Debt skyrocketed 71.16% in 2020, then decreased 1.0% in 2021.
  • Over 5 years, Total Debt stood at $229.5 million in 2018, then fell by 0.17% to $229.2 million in 2019, then surged by 71.16% to $392.2 million in 2020, then dropped by 1.0% to $388.3 million in 2021, then rose by 2.02% to $396.1 million in 2022.
  • According to Business Quant data, Total Debt over the past three periods came in at $396.1 million, $393.2 million, and $388.3 million for Q2 2022, Q1 2022, and Q4 2021 respectively.